Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.50 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 8/20 | 0.46 |
| ▸ | BRD1 | O95696 | 5/20 | 0.46 |
| ▸ | BRPF3 | Q9ULD4 | 5/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19682479 | 0.83 | TRPV4 (0.70) | PTGES2TRPV4BRPF1BRD1BRPF3 | |
| SCHEMBL20743622 | 0.81 | BRPF1 (0.52) | TRPV4BRPF1BRD1BRPF3BRD9 | |
| SCHEMBL3274528 | 0.80 | TRPV4 (0.47) | PTGES2TRPV4CA12CA1CA2 | |
| SCHEMBL1798881 | 0.80 | EPAS1 (0.49) | TRPV4BRPF1BRD1BRPF3BRD9 | |
| SCHEMBL14925398 | 0.77 | PDIA6 (0.47) | PTGES2TRPV4CA12CA1CA2 | |
| SCHEMBL15956295 | 0.76 | PTGES2 (0.47) | PTGES2TRPV4BRPF1BRD1BRPF3 | |
| SCHEMBL30909386 | 0.76 | TRPV4 (0.45) | TRPV4BRPF1BRD1BRPF3BRD9 | |
| SCHEMBL1804739 | 0.75 | PKM (0.55) | PKMPTGES2TRPV4CA12CA1 | |
| SCHEMBL29469916 | 0.75 | MCOLN3 (0.55) | PKMPTGES2TRPV4CA12CA1 | |
| SCHEMBL51171 | 0.75 | MCOLN3 (0.55) | PKMPTGES2TRPV4CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12357603-B2 | Acyl sulfonamides for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-15 | — | — | US | disclosed |
| EP-3959202-B1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AG (DE) | 2023-08-16 | — | — | EP | disclosed |
| CN-110997651-B | Novel tetrazole compounds and their use in the treatment of tuberculosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-01-03 | — | — | CN | disclosed |
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | THE BROAD INSTITUTE, INC. | 2022-07-21 | — | — | US | disclosed |
| CN-114072394-A | Acylsulfonamides for the treatment of cancer | 拜耳股份公司 | 2022-02-18 | — | — | CN | disclosed |
| US-11072591-B2 | Tetrazole compounds and their use in the treatment of tuberculosis | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-27 | — | — | US | disclosed |
| US-11072591-B2 | Tetrazole compounds and their use in the treatment of tuberculosis | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-07-27 | — | — | US | disclosed |
| EP-3668856-B1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| EP-3668856-B1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-06-23 | — | — | EP | disclosed |
| WO-2020216701-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2020-10-29 | — | — | WO | disclosed |
| US-20200231555-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| US-20200231555-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-07-23 | — | — | US | disclosed |
| EP-3668856-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-06-24 | — | — | EP | disclosed |
| CN-110997651-A | Novel tetrazole compounds and their use in the treatment of tuberculosis | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019034729-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034729-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-21 | — | — | WO | disclosed |
| EP-2594554-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-2012008435-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226279-A1 | ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | PKM 2459/4885PTGES2 3466/4885TRPV4 4696/4885 |
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC2R, NR3C2, REN | PKM 3538/4885PTGES2 4149/4885TRPV4 2680/4885 |
| US-12357603-B2 | Acyl sulfonamides for treating cancer | KAT6A, KAT6B, KAT2A | PKM 2459/4885PTGES2 3466/4885TRPV4 4696/4885 |
| US-20200231555-A1 | NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS | TBL1XR1, TBCA, TST | PKM 893/4885PTGES2 2951/4885TRPV4 1491/4885 |
| US-11072591-B2 | Tetrazole compounds and their use in the treatment of tuberculosis | TST, TBCA, TBCD | PKM 777/4885PTGES2 2393/4885TRPV4 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.